Health organization American Diabetes Association (ADA) revealed on Friday that diabetes was the main risk factor for the accelerated advancement to a severe state in Japanese COVID-19 patients based on the findings of a new study.
This study, which was presented by Dr Shizuka Kaneko, MD, PhD at the association's virtual 81st Scientific Sessions, focused on patients characterised as "moderate" by the Osaka Prefectural Government stratification. A retrospective analysis in type 2 diabetes patients compared with a control was conducted. Of the total 102 patients, 49% were type 2 diabetes patients.
About 88% of patients moving from the moderate to the severe classification had type 2 diabetes. A total of 24.5% moved from the moderate to the severe classification, with 17.6%, including 88.9% with type 2 diabetes, ventilated and transferred to another hospital. 6.9%, including 71.4% with type 2 diabetes, died after ventilation. About 24.5% diabetic patients improved, revealed the association.
The ADA's 81st Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention and care, will be held virtually 25-29 June 2021. Leading physicians, scientists and health care professionals from around the world will unveil cutting-edge research, treatment recommendations and advances toward a cure for diabetes.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes